ATE504570T1 - Tartratsalz aus isofagomin und verwendungsverfahren dafür - Google Patents
Tartratsalz aus isofagomin und verwendungsverfahren dafürInfo
- Publication number
- ATE504570T1 ATE504570T1 AT07252109T AT07252109T ATE504570T1 AT E504570 T1 ATE504570 T1 AT E504570T1 AT 07252109 T AT07252109 T AT 07252109T AT 07252109 T AT07252109 T AT 07252109T AT E504570 T1 ATE504570 T1 AT E504570T1
- Authority
- AT
- Austria
- Prior art keywords
- isofagomin
- salt
- tartrate salt
- gaucher disease
- isofagomine tartrate
- Prior art date
Links
- 150000003892 tartrate salts Chemical class 0.000 title abstract 2
- ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80802006P | 2006-05-24 | 2006-05-24 | |
| US89071907P | 2007-02-20 | 2007-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE504570T1 true ATE504570T1 (de) | 2011-04-15 |
Family
ID=38462442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07252109T ATE504570T1 (de) | 2006-05-24 | 2007-05-23 | Tartratsalz aus isofagomin und verwendungsverfahren dafür |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7501439B2 (de) |
| EP (1) | EP1860101B1 (de) |
| JP (1) | JP5292605B2 (de) |
| AT (1) | ATE504570T1 (de) |
| AU (1) | AU2007202359B2 (de) |
| BR (1) | BRPI0706114A2 (de) |
| CA (1) | CA2590122C (de) |
| DE (1) | DE602007013648D1 (de) |
| DK (1) | DK1860101T3 (de) |
| IL (1) | IL183415A (de) |
| MX (1) | MX2007006175A (de) |
| PL (1) | PL1860101T3 (de) |
| PT (1) | PT1860101E (de) |
| WO (1) | WO2007140212A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006254796B2 (en) * | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| WO2007150064A2 (en) | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| CA2688850C (en) * | 2007-05-22 | 2015-08-11 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
| EP2946785B1 (de) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Verfahren zur vorhersage der reaktion auf die behandlung von krankheiten mit pharmakologischen chaperonen |
| GB2480159A (en) * | 2008-11-14 | 2011-11-09 | Parkinson S Inst | Compositions and methods for the treatment of altered a-synuclein function |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| KR101880411B1 (ko) | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| CA2840224C (en) * | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| EP2806875B1 (de) | 2012-01-25 | 2017-07-19 | Proteostasis Therapeutics, Inc. | Verbindungen zur modulierung einer proteasomaktivität |
| CN104519905A (zh) | 2012-03-02 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 用于治疗iii型戈谢病的组合物和方法 |
| CA2868459A1 (en) | 2012-03-27 | 2013-10-03 | Amicus Therapeutics, Inc. | Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof |
| JP2015512913A (ja) | 2012-03-28 | 2015-04-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 |
| EP3318277A1 (de) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen |
| DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
| KR20240171186A (ko) * | 2017-10-26 | 2024-12-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 글루코세레브로시다제 및 이소파고민을 포함하는 제제 |
| WO2020006269A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| JP7561632B2 (ja) | 2018-06-27 | 2024-10-04 | キネタ， インコーポレイテッド | プロテアソーム活性増強化合物 |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| WO2020219874A1 (en) * | 2019-04-25 | 2020-10-29 | Shire Human Genetic Therapies, Inc. | Isofagomine salts, methods of use and formulations |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844102A (en) * | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-23 EP EP07252109A patent/EP1860101B1/de not_active Not-in-force
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en not_active Ceased
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL183415A (en) | 2012-03-29 |
| CA2590122A1 (en) | 2007-11-24 |
| WO2007140212A2 (en) | 2007-12-06 |
| JP5292605B2 (ja) | 2013-09-18 |
| US20090176830A1 (en) | 2009-07-09 |
| US7863453B2 (en) | 2011-01-04 |
| AU2007202359A1 (en) | 2007-12-13 |
| DK1860101T3 (da) | 2011-07-25 |
| AU2007202359B2 (en) | 2012-02-16 |
| IL183415A0 (en) | 2007-09-20 |
| MX2007006175A (es) | 2009-02-16 |
| EP1860101A1 (de) | 2007-11-28 |
| PL1860101T3 (pl) | 2011-10-31 |
| PT1860101E (pt) | 2011-07-12 |
| EP1860101B1 (de) | 2011-04-06 |
| US7501439B2 (en) | 2009-03-10 |
| BRPI0706114A2 (pt) | 2008-11-18 |
| US20070281975A1 (en) | 2007-12-06 |
| WO2007140212A3 (en) | 2008-12-24 |
| JP2007314540A (ja) | 2007-12-06 |
| DE602007013648D1 (de) | 2011-05-19 |
| CA2590122C (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE504570T1 (de) | Tartratsalz aus isofagomin und verwendungsverfahren dafür | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| MX350898B (es) | Sal de malato de n(4-{[6,7-bis(metiloxi) quinolin-4-il]oxi}fenil)- n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer. | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| EP1916964A4 (de) | Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten | |
| WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
| NZ599343A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| DK2194053T3 (da) | Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet. | |
| ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
| ATE441632T1 (de) | Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| DE602006013271D1 (de) | Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen | |
| EA201001773A1 (ru) | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина | |
| UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
| MX2009003974A (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. | |
| DE502006003194D1 (de) | Salze substituierter allophansäureester und deren verwendung in arzneimitteln | |
| ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
| ATE527997T1 (de) | Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien | |
| DE60331654D1 (de) | Nicht-radioaktives Strontiummittel zur Behandlung von Krebs | |
| ATE440836T1 (de) | Verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1860101 Country of ref document: EP |